Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Revenues up 9% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
3Q Revenues: $4.1 billion (+9%)  

3Q Earnings: $692 million (loss of $713 million 3Q12)

YTD Revenues: $11.9 billion (-11%)

YTD Earnings: $1.8 billion (+17%)

Comments: U.S. sales increased 1% to $2.0 billion in the quarter. International sales were up 19% to $2.0 billion. Yervoy sales were up 33% to $238 million. Onglyza/Kombiglyze sales were up 19% to $211 million. Sprycel sales grew 20% to $316 million. Orencia sales grew 22% to $375 million. Baraclude sales were $378 million, up 9%. Eliquis, approved in December to prevent strokes caused by an irregular heartbeat, had modest sales of $41 million. Abilify sales were down 16% to $569 million, Avapro/Avalide sales were down 25% to $71 million, and Plavix sales were down 34% to $42 million, impacted by generic competion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters